
View larger version (62K):
[in a new window]
|
Figure 1. Effect of different tissue sites on RF tumor ablation effectiveness. A, Tumor implanted in kidney. B, Tumor implanted subcutaneously. C, Tumor implanted in lung. Significantly smaller coagulation diameter (mean, 7 mm) was achieved in the kidney tissue site (A) in comparison to that in subcutaneous (B) and lung (C) tissue sites. In A, viable and perfused tumor, as evidenced by the uptake of 2% Evans blue dye (arrows), persists around the central ablation zone. In B, greater coagulation diameter (9 mm [arrows]) is observed in subcutaneous tumors than in kidney tumors, but viable tumor tissue persists in the tumor margins. In C, greatest coagulation diameter (14 mm) was observed in lung tumors. Tumor was completely treated in this case, including a margin of normal surrounding lung parenchyma (black arrows). White arrow indicates tumor-ablation margin interface.
|